The Linked Clinical Trials initiative is a drug repositioning initiative designed by The Cure Parkinson’s Trust. This initiative not only prioritises potential new therapeutic candidates, but also explores the best way of bringing them into trial, to ensure synergy between trials in the data collected to allow maximum comparison.
Parkinson’s as a disease area has lacked innovation and therefore new treatments. There is only one gold standard treatment for Parkinson’s which has been used for over 40 years.
The new biochemical understanding has highlighted a number of potential new routes to treat Parkinson’s - with the ultimate aim of slowing, halting or reversing the disease progression. This new biochemical thinking has highlighted that drugs from other disease areas can be brought into Parkinson’s.
In September 2012, The Cure Parkinson’s Trust hosted the first Linked Clinical Trials (LCT) research conference in Grand Rapids, Michigan, USA. Chaired by Professor Patrik Brundin of the Van Andel Institute, we coordinated a gathering of some of the world’s leading Parkinson’s researchers to analyse a series of potential drug repositioning targets, with the aim of selecting between 5-10 potential treatments to move into clinical trial.
In addition, we invited representatives of several major global funding sources including The Michael J Fox Foundation and the US National Institutes of Health to contribute to the discussion to ensure these trials can move forward as seamlessly as possible.
In August 2013 we hosted our second Linked Clinical Trials (LCT) meeting in the spectacular surroundings of Cumberland Lodge, Windsor. Once again, chaired by Professor Patrik Brundin of the Van Andel Institute, we coordinated a gathering of some of the world’s leading Parkinson’s researchers to analyse a second series of potential drug repositioning targets, with the aim of selecting between 5-10 potential treatments to move into clinical trial in the next 18 months.
Crucially the first session of the meeting discussed optimal clinical trial design currently The Cure Parkinson's Trust is developing strategies to bring the 2012 and the 2013 candidates forward to trial within the agreed format, within a logical and deliverable timeframe.
Click here to read more (article published in the Journal of Parkinson's disease)
Please contact Helen for further details.